On April 7, 2023, Texas Judge Matthew J. Kacsmaryk ordered the Food and Drug Administration to invalidate its 23-year-old approval of mifepristone, one of the components of a medication abortion, a ruling that would effectively remove the drug from the market. Hours later, a Federal Judge in Washington state ordered the FDA to not make any changes to mifepristone’s current availability. Since then, a Federal Appeals Court has ruled that it can stay on the market, but imposed sharp restrictions for accessing it.